Press release – For immediate release
December 3, 2025 – 5:45 pm CET

Disclosure of total number of voting rights and number of shares in the
capital as of November 30, 2025

Pursuant to article L-223-8 II of the French “code de Commerce” and
223-16 of the AMF’s General Regulations.

Sophia Antipolis, France


Total number of shares 36,741,587
Number of real voting rights*
36,669,667
(excluding treasury shares**)
Theoretical number of voting rights*
36,718,387
(including treasury shares**)
(*) Class E preference shares are non-voting
(**) pursuant to article 223-11 of the AMF’s General Regulations



About Median Technologies: Pioneering innovative software as a medical device and
imaging services, Median Technologies harnesses cutting-edge AI to enhance the
accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO,
which provides medical image analysis and management in oncology trials, and eyonis®,
an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers
biopharmaceutical entities and clinicians to advance patient care and expedite the
development of novel therapies. The French-based company, with a presence in the U.S.
and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for
the French SME equity savings plan scheme (PEA-PME). For more information, visit
www.mediantechnologies.com.


Contacts

Median Technologies Press – Ulysse Communication
Emmanuelle Leygues Bruno Arabian
VP, Corporate Marketing & Financial Communications +33 6 87 88 47 26
+33 6 10 93 58 88 barabian@ulysse-communication.com
emmanuelle.leygues@mediantechnologies.com Nicolas Entz
+33 6 33 67 31 54
nentz@ulysse-communication.com
Investors - ACTIFIN
Ghislaine Gasparetto
+33 6 85 36 76 81
ghislaine.gasparetto@seitosei-actifin.com




1|Page